The First Clinical Use of a Novel Cold Storage System of Donor Hearts

Naito, et al.
Journal of Heart and Lung Transplantation
April 2019; Volume 38, Issue 4, S44.

Purpose : Current cold storage heart preservation technique is associated with wide fluctuation of organ temperature and may result in freeze injury. SheraPak™ Cardiac Transport System (CTS) (Paragonix Technologies, MA, USA) was recently approved in the United States for clinical use. This single-use disposable device is designed for static hypothermic preservation of a donor heart during transport. We report the first clinical use of the SheraPak™ CTS.

Methods : Since July 2018, the SheraPak™ CTS has been used in 6, non-consecutive heart transplant procedures at a single institution. All organs were procured from brain dead donors and had normal systolic function. Donor hearts were procured in standard fashion and positioned within the SheraPak™ CTS per the manufacturer’s instructions. The hearts were removed from the system in the recipient operating room and prepared for implantation in standard fashion.

Results : Six recipients (5 male; mean age 60.3 ± 19.1 years) underwent heart transplantation using donor hearts transported with SheraPak™ CTS. All donors were categorized as PHS high risk and 5 of them were hepatitis C positive. Donor heart transportation time within the shipper was 24 to 205 (109.67 ± 66.60) min and donor heart total ischemic time was 116 to 312 (225 ± 70) min. Donor hearts were preserved at static hypothermia with a mean temperature of 5.99 ± 0.52°C. Among the patients transplanted there was no observed primary graft failure, and the ICU length of stay ranged from 3 to 21 (8.5 ± 6.3) days. All recipients are alive and well beyond 30 days with normal systolic function at discharge (LVEF 72± 6%).

Conclusion: The SheraPak™ CTS provides consistent organ temperature regulation throughout the transport observed process. Organs transported using this system demonstrated normal perioperative function even including an organ with more than 5 hours of total ischemic time. This system may decrease cold injury during organ transportation and increase the safe interval of tolerable cold ischemia.

Paragonix Technologies, Inc
245 First Street, 18th Floor
Cambridge, Massachusetts 02142